25 November 2014 : Original article
Low Paraoxonase 1 Arylesterase Activity and High von Willebrand Factor Levels are Associated with Severe Coronary Atherosclerosis in Patients with Non-Diabetic Stable Coronary Artery Disease
Jieying DingAE, Qizhi ChenBE, Xing ZhuangCD, Zhilei FengDE, Lili XuE, Fuxiang ChenAEDOI: 10.12659/MSM.890911
Med Sci Monit 2014; 20:2421-2429
Abstract
BACKGROUND: Paraoxonase 1 (PON1) activity and von Willebrand factor (VWF) release are associated with lesion initiation in atherosclerosis. Diabetes can complicate coronary artery disease (CAD) due to the production of advanced glycation end products. This study evaluated PON1 activity and VWF levels in non-post-acute coronary syndrome, stable CAD (SCAD) patients without diabetes.
MATERIAL AND METHODS: Non-diabetic SCAD patients and patients experiencing acute stress periods were selected (n=130). Forty-seven cases with normal coronary angiography and 50 healthy individuals served as controls. The non-diabetic SCAD group was then stratified into single-vessel lesions, multiple-vessel lesions, and mild or severe luminal stenosis according to the number and the degree of luminal stenoses. Serum PON1 paraoxonase and arylesterase activities, and plasma VWF levels were measured, as well as serum total cholesterol, total triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and apolipoprotein A1. PON1 arylesterase activity was detected with an ordinary chemistry system using a novel phenylacetate derivative.
RESULTS: Both PON1 paraoxonase and arylesterase were lower in the non-diabetic SCAD group, but VWF levels were higher (versus controls, all P<0.001). PON1 paraoxonase activity (OR=0.991), PON1 arylesterase activity (OR=0.981), and VWF (OR 2.854) influenced SCAD in multiple logistic regression. Decreased PON1 arylesterase activity and increased VWF levels were associated with severe atherosclerosis in non-diabetic SCAD patients. We also observed a slight negative correlation between VWF and PON1 paraoxonase/arylesterase.
CONCLUSIONS: PON1 and VWF are detectable markers that may predict the severity of stenoses, ideally facilitating a non-diabetic SCAD diagnosis before the sudden onset of life-threatening symptoms.
Keywords: Aryldialkylphosphatase - blood, Case-Control Studies, Coronary Artery Disease - enzymology, Coronary Stenosis - complications, Diabetes Mellitus - blood, Logistic Models, Multivariate Analysis, ROC Curve, Reproducibility of Results, von Willebrand Factor - metabolism
Editorial
01 January 2025 : Editorial
Editorial: The Human Cell Atlas. What Is It and Where Could It Take Us?DOI: 10.12659/MSM.947707
Med Sci Monit 2025; 31:e947707
In Press
Review article
Characteristics and Associated Risk Factors of Broad Ligament Hernia: A Systematic ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.946710
Clinical Research
Cost-Effective Day Surgery for Arteriovenous Fistula Stenosis: A Viable Model for Hemodialysis PatientsMed Sci Monit In Press; DOI: 10.12659/MSM.946128
Clinical Research
Impact of Periodontal Treatment on Early Rheumatoid Arthritis and the Role of Porphyromonas gingivalis Anti...Med Sci Monit In Press; DOI: 10.12659/MSM.947146
Clinical Research
C-Reactive Protein, Uric Acid, and Coronary Artery Ectasia in Patients with Coronary Artery DiseaseMed Sci Monit In Press; DOI: 10.12659/MSM.947158
Most Viewed Current Articles
17 Jan 2024 : Review article 6,963,884
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
16 May 2023 : Clinical Research 700,363
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Mar 2024 : Editorial 23,797
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...DOI :10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
28 Jan 2024 : Review article 18,566
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and FutureDOI :10.12659/MSM.943912
Med Sci Monit 2024; 30:e943912